厄贝沙坦氢氯噻嗪治疗轻中度高血压的疗效观察  

Clinical Observation of Irbesartan and Hydrochlorothiazide Irbesartan on the Treatment of Essential Hypertension

作　　者：刘红军[1] 高娅丽[1] 

机构地区：[1]北京交通大学医院,北京市100044

出　　处：《临床合理用药杂志》2012年第6期41-42,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察厄贝沙坦氢氯噻嗪治疗轻中度原发性高血压的疗效及安全性。方法选取轻中度原发性高血压患者80例,随机分为两组,观察组(40例)服用厄贝沙坦氢氯噻嗪治疗,对照组(40例)服用厄贝沙坦治疗,4周后根据血压决定维持原剂量或原有剂量加倍;总疗程8周。结果观察组总有效率为97.5%,对照组总有效率为82.5%,两组比较差异有统计学意义(P<0.01),两组不良反应发生率均为5%。结论厄贝沙坦氢氯噻嗪治疗轻中度高血压疗效明显,不良反应发生率低。Objective To study the effect and safety of the light - moderate hypertension treatment using irbesartan and hydrochlorothiazide irbesartan. Methods Selected light - moderate hypertension patients were randomly split into 2 groups, one group was treated with hydrochlorothiazide irbesartan while irbesartan used for the other group for comparison. Total treatment period is 8 months, based on 4 months observation to decide either keep the current level or double it. Results Total treatment efficiency using hydrochlorothiazide irbesartan is 97.5%, while using irbesartan the efficiency is 82.5%, substantial difference observed （P 〈 0. 01 ）, the occurrence of negative reaction for both groups is 5%. Conclusion Using hydrochlorothiazide irbesartan is effective for light - moderate hypertension, negative effect occurrence is low.

关 键 词：高血压 厄贝沙坦氢氯噻嗪 厄贝沙坦 

分 类 号：R544.1[医药卫生—心血管疾病]